Lamellar Biomedical Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Lamellar Biomedical Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10576
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:18
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Lamellar Biomedical Ltd (Lamellar Biomedical) is a biotechnology company that develops medical products using based on mimetics of extra-alveolar lamellar bodies. The company develops products using its proprietary Lamellasome technology that are mimetics of native extra-alveolar lamellar that can be used for diseases associated with dry or sticky mucosal surfaces such as cystic fibrosis, radiotherapy induced xerostomia and dry eye disease. Its lead compound, Visco-ease (OXB/1-20) is used in treatment of RIX in head and neck cancer. The company also develops Lamelleye (CXB/1-14) and PMB/1-nn for the treatment of DED and CF. Lamellar Biomedical is headquartered in Glasgow, the UK.

Lamellar Biomedical Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Lamellar Biomedical Raises USD7.4 Million in Series C Financing 10
Lamellar Biomedical Raises US$5 Million In Series A Financing 11
Private Equity 12
Lamellar Biomedical Raises USD5.3 Million in Private Equity Financing 12
Partnerships 13
Lamellar Biomedical Enters into Research Agreement with University of Edinburgh 13
Equity Offering 14
Lamellar Biomedical Raises USD3.6 Million in Rights offering of Shares 14
Lamellar Biomedical Ltd – Key Competitors 15
Lamellar Biomedical Ltd – Key Employees 16
Lamellar Biomedical Ltd – Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
About GlobalData 18
Contact Us 18
Disclaimer 18

List of Tables
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lamellar Biomedical Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Lamellar Biomedical Raises USD7.4 Million in Series C Financing 10
Lamellar Biomedical Raises US$5 Million In Series A Financing 11
Lamellar Biomedical Raises USD5.3 Million in Private Equity Financing 12
Lamellar Biomedical Enters into Research Agreement with University of Edinburgh 13
Lamellar Biomedical Raises USD3.6 Million in Rights offering of Shares 14
Lamellar Biomedical Ltd, Key Competitors 15
Lamellar Biomedical Ltd, Key Employees 16

List of Figures
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Lamellar Biomedical Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Lamellar Biomedical Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • VGI Global Media Public Co Ltd:企業の戦略・SWOT・財務情報
    VGI Global Media Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary VGI Global Media Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Endeavor Energy Resources LP:石油・ガス:M&Aディール及び事業提携情報
    Summary Endeavor Energy Resources LP (Endeavor Energy) is an independent oil and gas company that acquires, explores, develops and produces crude oil and natural gas properties. The company has operations in the Delaware Basin which offers horizontal and vertical drilling in Winkler, Ward, Loving, R …
  • Kina Petroleum Ltd (KPL):石油・ガス:M&Aディール及び事業提携情報
    Summary Kina Petroleum Limited (KPL) is an upstream oil and gas company that focuses on exploration, development and production activities. It has operations in Papua New Guinea (PNG) and Australia. The company focuses on participating in highly prospective oil and gas acreage positions near to prov …
  • Grasim Industries Limited:企業の戦略・SWOT・財務情報
    Grasim Industries Limited - Strategy, SWOT and Corporate Finance Report Summary Grasim Industries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Delticom AG:企業の戦略・SWOT・財務情報
    Delticom AG - Strategy, SWOT and Corporate Finance Report Summary Delticom AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Affibody AB:製薬・医療:M&Aディール及び事業提携情報
    Summary Affibody AB (Affibody) is a biotech company that discovers and develops next generation biopharmaceuticals and related drugs. The company discovers and develops drugs based on its proprietary technology platforms such as Albumod and Affibody molecules. Its Affibody molecules are a class of a …
  • Curadev Pharma Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Curadev Pharma Pvt Ltd (Curadev Pharma) is a small molecule drug discovery company that manufactures, discovers, and delivers formulations. The company manufactures formulations and APIs such as cyclodextrin in collaboration with the University of Greenwich and creates and out-licenses pre-I …
  • Institute of Organic Chemistry and Biochemistry AS CR vvi:製薬・医療:M&Aディール及び事業提携情報
    Summary Institute of Organic Chemistry and Biochemistry AS CR vvi (IOCB) is a research institute that offers organic chemistry and biochemistry for medical and environmental applications. The institute’s scientific research includes the fields of physico-organic chemistry and biochemistry, molecular …
  • Machavert Pharmaceuticals LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Machavert Pharmaceuticals LLC (Machavert Pharmaceuticals) is a bio-pharmaceutical company which develops novel non-toxic medicines for the treatment of cancer and autoimmune diseases. Its lead drug candidate MP1000, a nanoparticulate liposomal phospholipid immune-modulating agent exhibits an …
  • InCarda Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary InCarda Therapeutics Inc (InCarda) is a biopharmaceutical company that concentrates on the development of transformative therapies for cardiovascular conditions through the inhalation route. The company’s lead product candidate includes InRhythm, an inhaled antiarrhythmic for acute treatment …
  • Technogenetics srl:医療機器:M&Aディール及び事業提携情報
    Summary Technogenetics srl (Technogenetics), a subsidiary of Shanghai Kehua Bio-engineering Co Ltd, is an immunodiagnostics and molecular genetics company that offers reagents and instruments in the field of biotechnology and pharmacology. The company provides immunodiagnostics products in the areas …
  • HTC Corporation:戦略・SWOT・企業財務分析
    HTC Corporation - Strategy, SWOT and Corporate Finance Report Summary HTC Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Emirates Telecommunications Group Company PJSC:企業のM&A・事業提携・投資動向
    Emirates Telecommunications Group Company PJSC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Emirates Telecommunications Group Company PJSC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business descriptio …
  • Shimizu Corporation:企業の戦略・SWOT・財務分析
    Shimizu Corporation - Strategy, SWOT and Corporate Finance Report Summary Shimizu Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Urenco Ltd:企業の戦略・SWOT・財務情報
    Urenco Ltd - Strategy, SWOT and Corporate Finance Report Summary Urenco Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • ACB Securities Co Ltd:企業の戦略的SWOT分析
    ACB Securities Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Green Plains Inc.:企業の戦略・SWOT・財務情報
    Green Plains Inc. - Strategy, SWOT and Corporate Finance Report Summary Green Plains Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Mitsubishi Estate Co., Ltd. (8802):企業の財務・戦略的SWOT分析
    Mitsubishi Estate Co., Ltd. (8802) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Mauna Kea Technologies SAS (MKEA):医療機器:M&Aディール及び事業提携情報
    Summary Mauna Kea Technologies SAS (MKT) is an endomicroscopy device manufacturer. The company develops, manufactures and distributes tools to visualize and detect cellular abnormalities during endoscopic procedures. It provides confocal laser endomicroscopy platform. MKT’s cellvizio is an endomicro …
  • China Southern Airlines Company Limited:企業のM&A・事業提携・投資動向
    China Southern Airlines Company Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Southern Airlines Company Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed re …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆